Mesenchymal Stromal Cell Therapy for Thoracic Surgeons: An UpdateReview Published on 2023-11-222024-09-05 Journal: Journal of Personalized Medicine [Category] update2024, [키워드] Bronchopleural fistula drug delivery drug loading imaging lipofilling oncology pleural mesothelioma regenerative medicine stromal cell Thoracic Surgery [DOI] 10.3390/jpm13121632 PMC 바로가기 [Article Type] Review
An International Society for Cell and Gene Therapy Mesenchymal Stromal Cells Committee editorial on overcoming limitations in clinical trials of mesenchymal stromal cell therapy for coronavirus disease-19: time for a global registryArticle Published on 2022-11-012022-11-15 Journal: Cytotherapy [Category] 진단, [키워드] clinical trial Committee coronavirus limitation Society stromal cell therapy [DOI] 10.1016/j.jcyt.2022.07.010 PMC 바로가기
Preclinical safety evaluation and tracing of human mesenchymal stromal cell spheroids following intravenous injection into cynomolgus monkeysResearch article Published on 2022-10-012022-10-05 Journal: Biomaterials [Category] Coronavirus, 비임상, [키워드] addressed administration ambient Blood blood vessel Cell death demonstrated dissociate Efficacy feasible Host hypoxic condition injection intravenous Intravenous injection less lung Mesenchymal stem cells mice Monkey MSC MSCs multiple sclerosis occurred Osteoarthritis physiological change Preclinical promote retention Safe Safety Single Cell small blood vessel small vessel Spheroid Stress stromal cell survival viability wound healing [DOI] 10.1016/j.biomaterials.2022.121759 [Article Type] Research article
Proceedings of the ISCT scientific signature series symposium, “Advances in cell and gene therapies for lung diseases and critical illnesses”: International Society for Cell & Gene Therapy, Burlington VT, US, July 16, 2021Review article Published on 2022-08-012022-10-05 Journal: Cytotherapy [Category] 비임상, [키워드] biennial bioengineering Biology Cell Cell therapy cell-based therapies Critical Critical illness European Evolution Gene therapy illness illnesses independent ISCT Lung disease Lung injury mechanism Mesenchymal stromal cell mitigate MSCs Patient preclinical data Proceeding pulmonary reflect respiratory Respiratory disease Sery signature Society state stromal cell symposium therapy thought took place transfer translated University of Vermont vectors [DOI] 10.1016/j.jcyt.2021.11.007 [Article Type] Review article
Mesenchymal stromal cell therapy for acute respiratory distress syndrome due to coronavirus disease 20192019년 코로나바이러스로 인한 급성호흡곤란증후군에 대한 중간엽 기질세포 치료Article Published on 2022-08-012022-09-12 Journal: Cytotherapy [Category] 진단, [키워드] 95% CI 95% confidence interval acute lung injury acute respiratory distress acute respiratory distress syndrome Allogeneic anti-inflammatory property ARDS C-reactive protein case sery cells clinical outcomes coronavirus disease COVID-19 COVID-19-associated ARDS declined discharged dose eligible follow-up period high mortality hospital Inflammatory cytokine intensive care Kidney injury less liver Lung disease mechanical ventilation mechanically ventilated median time Mesenchymal stromal cell Mesenchymal stromal cells moderate MSC MSCs nine Patient patients patients died remained Remestemcel-L requiring supplemental oxygen resulting Safe shown significantly stromal cell syndrome therapy treat treated were excluded [DOI] 10.1016/j.jcyt.2022.03.006 PMC 바로가기 [Article Type] Article
The clinical efficacy and safety of mesenchymal stromal cells for patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials코로나19 환자를 위한 중간엽 기질세포의 임상적 효능 및 안전성: 무작위 대조 시험의 체계적인 검토 및 메타 분석Meta-Analysis Published on 2022-08-012022-09-11 Journal: Journal of infection and public health [Category] 신약개발, 임상, [키워드] 28-day mortality 95% CI addition adverse event adverse events AEs appear Clinical efficacy Clinical improvement Clinical outcome clinical outcomes ClinicalTrials Cochrane Library control group controls COVID-19 help IMPROVE investigated Mesenchymal stromal cell Mesenchymal stromal cells Meta-analysis Mortality mortality rate MSC MSCs OVID Patient patients patients with COVID-19 Placebo placebos Randomized controlled trial Randomized controlled trials RCT RCTs risk Safe SARS-CoV-2 searched serious AE serious AEs significantly higher significantly lower stromal cell stromal cells systematic review therapeutic option treat Treatment [DOI] 10.1016/j.jiph.2022.07.001 PMC 바로가기 [Article Type] Meta-Analysis
Updated Living Systematic Review and Meta-analysis of Controlled Trials of Mesenchymal Stromal Cells to Treat COVID-19: A Framework for Accelerated Synthesis of Trial Evidence for Rapid Approval-FASTER ApprovalCOVID-19를 치료하기 위한 중간엽 간질 세포의 통제된 시험에 대한 업데이트된 살아있는 체계적인 검토 및 메타 분석: 신속한 승인-빠른 승인을 위한 시험 증거의 가속화된 합성을 위한 프레임워크Meta-Analysis Published on 2022-07-202022-09-11 Journal: Stem cells translational medicine [Category] 임상, [키워드] accelerate accelerated acute respiratory distress acute respiratory distress syndrome acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 appear approval ARDS Clinical studies clinical study conducted Consistency Control Controlled controls coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 criteria Critical death Endpoint evaluate Evidence Exosomes Extracellular Extracellular vesicles facilitate framework heterogeneity Hospital stay identify IMPROVE ISCT Master protocol mean difference Mesenchymal stem cells Mesenchymal stromal cell Mesenchymal stromal cells Meta-analysis Microvesicles moderate Mortality MSC MSC-EVs exosomes MSCs non-randomized study outcome Oxygenation Patient Pneumonia PROSPERO protocol random-effect random-effects Random-effects meta-analysis Randomized controlled trial Rapid reduce reduce mortality Relative risk reported respiratory distress Respiratory distress syndrome review risk of bia risk of death RoB SARS-CoV-2 Sepsis severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 Society stromal cell stromal cells synthesis systematic review treat Treatment [DOI] 10.1093/stcltm/szac038 PMC 바로가기 [Article Type] Meta-Analysis
Safety and efficacy of mesenchymal stem cells in severe/critical patients with COVID-19: A systematic review and meta-analysisArticle Published on 2022-07-092022-10-06 Journal: EClinicalMedicine [Category] 진단, [키워드] 95% CI adverse event AEs applied benefit cellular therapy China Chinese CNKI Cochrane Library control group Coronavirus disease-19 (COVID-19) COVID-19 Critical database Descriptive analysis development disease category dose doses Efficacy Efficacy and safety Egger Free heterogeneity in-hospital mortality in-hospital mortality rate Innovation less Mesenchymal stem cells Meta-analysis mortality rate MSC MSCs optics original Patient patients with COVID-19 Placebo plan Primary outcome Program reduce mortality Safe Safety Science searched Secondary outcomes significant difference small sample size standard care standard treatment stem cell stromal cell subgroup analysis Support systematic review technology the disease Tianjin Trade Treatment Trial two groups Valley was performed were used Wuhan [DOI] 10.1016/j.eclinm.2022.101545 PMC 바로가기 [Article Type] Article
Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical TrialClinical Trial Published on 2022-07-042022-10-04 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 임상, [키워드] acute respiratory distress acute respiratory distress syndrome adverse effect ARDS bone Bone marrow cells cellular cellular therapy clinical Cohort control patient control patients COVID-19 COVID-19 disease Critical D-dimer value Dexamethasone Efficacy Endocarditis evaluate extracorporeal membrane oxygenation group high mortality High-flow nasal oxygen Immune cell Immune-mediated induce Inflammation Inflammatory response intensive care intensive care unit (ICU) interval intravenous infusion invasive Invasive mechanical ventilation limit mechanical ventilation median Mesenchymal stromal cells MSC MSC-treated MSCs nasal no significant difference observation outcome oxygen Patient patients phase phenotype Randomized controlled trial Regulatory reported required requiring supplemental oxygen Result Safe SARS-CoV-2 severe COVID-19 significantly higher significantly lower Statistical tests stimulate stroke stromal cell survival syndrome therapy tissue repair treated Trial [DOI] 10.3389/fimmu.2022.932360 PMC 바로가기 [Article Type] Clinical Trial
Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trialClinical Trial Published on 2022-06-282022-10-05 Journal: Stem Cell Research & Therapy [Category] 임상, [키워드] acute respiratory distress syndrome addition adverse effect approach ARDS ARDS patient ARDS patients Cell change clinical clinical trial control group correlated COVID-19 pandemic COVID-19 patient CRP level CT scan Cytokine storm demonstrated disease distress Features follow-up period functions IFN-g IL-10 IL-17 IL-1B IL-6 Inflammatory cytokines injection Intervention intervention group intravenous intravenous infusion Mesenchymal stromal cells Mild-to-moderate MSC MSCs Open-label Patient Registered registry required respiratory Safe Safety Sample size serum CRP serum cytokine serum cytokine level significant decrease significant increase single-center SPO standard care stromal cell study period syndrome therapy TNF-α UC-MSC UC-MSCs umbilical were assessed [DOI] 10.1186/s13287-022-02920-1 PMC 바로가기 [Article Type] Clinical Trial